GlassScriptPhysician profile
Rohan Matthews
NPI 1265143721
$7,720.05
in general payments reported to CMS, 2019-2025
16 companies · $3,830 in 2025
The $3,830 reported for 2025 was more than what 98% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,511 · 2024: $2,379 · 2025: $3,830.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,573 · Education: $147.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,573.31 |
| Education | $146.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $1,294.33 | 2023-2025 | Abilify Maintena, Rexulti, Abilify Asimtufii |
| Teva Pharmaceuticals USA, INC. | $1,226.18 | 2023-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Almatica Pharma LLC | $739.17 | 2023-2025 | Loreev Xr |
| Janssen Pharmaceuticals, INC | $658.85 | 2023-2025 | Invega Sustenna |
| Vanda Pharmaceuticals INC. | $651.30 | 2023-2025 | Fanapt, Hetlioz |
| Alkermes, INC. | $611.05 | 2023-2025 | Aristada, Lybalvi, Aristada Initio |
| Abbvie INC. | $582.03 | 2024-2025 | |
| Axsome Therapeutics, INC. | $500.12 | 2024-2025 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $453.14 | 2024-2025 | Cobenfy |
| Lundbeck LLC | $398.24 | 2023-2025 | Rexulti |
| Supernus Pharmaceuticals, INC. | $271.75 | 2023-2025 | Qelbree, Qelbree |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $210.80 | 2025 | Caplyta |
| Indivior INC. | $36.29 | 2024 | Perseris |
| Luye Pharma (USA) LTD. | $35.78 | 2025 | Erzofri Extended-Release |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $27.48 | 2025 | Rexulti |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $23.54 | 2024 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rohan Matthews listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.